Randomized, Placebo-Controlled Trial on the Renal and Systemic Hemodynamic Effects of Empagliflozin.

ABSTRACT:

Introduction

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve renal outcomes in type 2 diabetes mellitus (DM2) and chronic kidney disease (CKD). A decrease in renal blood flow (RBF) with attenuation of glomerular hyperfiltration may contribute. We examined renal and systemic hemodynamic effects of SGLT2i in relevant patient categories.

Methods

Using a double-blind placebo controlled cross-over design, we randomized patients with DM2 and estimated glomerular filtration rate (eGFR) > 60 ml/min per 1.73 m² (n = 16), patients with DM2 and eGFR from 20 to 60 ml/min per 1.73 m² (n = 17), and patients with nondiabetic CKD and eGFR from 20 to 60 ml/min per 1.73 m² (n = 16) to empagliflozin 10 mg daily or placebo for 4 w

SUBMITTER: Nielsen SF 

PROVIDER: S-EPMC11725969 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature